Beyond CAR-T therapy for pleural mesothelioma: emerging CAR-NK, CAR-macrophage, CAR-γδ T, and CAR-NKT cell therapies

Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor long-term outcomes and limited therapeutic options. Chimeric antigen receptor (CAR) T-cell therapy has shown promise in MPM, but its clinical efficacy remains constrained by poor tumor infiltration, an immunosuppressive tumor microenvironment (TME), cellular exhaustion, antigen heterogeneity, and treatment-related toxicity, as well as the logistical burden of autologous manufacturing. These limitations have motivated the development of alternative CAR platforms built on immune cell populations with distinct biological and therapeutic properties. In this review, we examine the preclinical and emerging clinical landscape of CAR-natural killer (CAR-NK), CAR-macrophage (CAR-M), CAR-γδ T-cell, and CAR-natural killer T-cell (CAR-NKT) therapies for MPM. We first discuss mesothelin (MSLN) and other tumor-associated antigens as candidate targets. We then evaluate how the biological attributes unique to each alternative effector population may address the limitations of conventional CAR-T therapy. We next examine strategies for allogeneic and “off-the-shelf” manufacturing, including the use of peripheral blood, cord blood, hematopoietic stem and progenitor cells, induced pluripotent stem cells, and established cell lines. Finally, we discuss next-generation engineering strategies, including cytokine armoring, immune checkpoint blockade, chemokine receptor engineering, and approaches to overcome host-versus-graft rejection. Collectively, current evidence supports CAR-NK, CAR-M, CAR-γδ T, and CAR-NKT cells as promising platforms for MPM, while underscoring the need for disease-specific preclinical validation and clinical investigation to determine how these approaches can be optimized for durable and safe therapeutic responses.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2026-11-21
DOI
https://doi.org/10.1186/s12967-026-09262-z
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Beyond CAR-T therapy for pleural mesothelioma: emerging CAR-NK, CAR-macrophage, CAR-γδ T, and CAR-NKT cell therapies

Yan-Ruide Li, Thomas Yuen, Shelby Yeh, Danna Marie Padua et al.
Journal of Translational Medicine
CAR-T cell therapy research
article

Beyond CAR-T therapy for pleural mesothelioma: emerging CAR-NK, CAR-macrophage, CAR-γδ T, and CAR-NKT cell therapies

Yan-Ruide Li, Thomas Yuen, Shelby Yeh, Danna Marie Padua, Coral Clune, Nicklaus Chui
article en

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor long-term outcomes and limited therapeutic options. Chimeric antigen receptor (CAR) T-cell therapy has shown promise in MPM, but its clinical efficacy remains constrained by poor tumor infiltration, an immunosuppressive tumor microenvironment (TME), cellular exhaustion, antigen heterogeneity, and treatment-related toxicity, as well as the logistical burden of autologous manufacturing. These limitations have motivated the development of alternative CAR platforms built on immune cell populations with distinct biological and therapeutic properties. In this review, we examine the preclinical and emerging clinical landscape of CAR-natural killer (CAR-NK), CAR-macrophage (CAR-M), CAR-γδ T-cell, and CAR-natural killer T-cell (CAR-NKT) therapies for MPM. We first discuss mesothelin (MSLN) and other tumor-associated antigens as candidate targets. We then evaluate how the biological attributes unique to each alternative effector population may address the limitations of conventional CAR-T therapy. We next examine strategies for allogeneic and “off-the-shelf” manufacturing, including the use of peripheral blood, cord blood, hematopoietic stem and progenitor cells, induced pluripotent stem cells, and established cell lines. Finally, we discuss next-generation engineering strategies, including cytokine armoring, immune checkpoint blockade, chemokine receptor engineering, and approaches to overcome host-versus-graft rejection. Collectively, current evidence supports CAR-NK, CAR-M, CAR-γδ T, and CAR-NKT cells as promising platforms for MPM, while underscoring the need for disease-specific preclinical validation and clinical investigation to determine how these approaches can be optimized for durable and safe therapeutic responses.

Journal of Translational Medicine
University of California, Los Angeles (US)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon